US Cancer Clinics Rush to Access Experimental Revolution Medicines Pancreatic Cancer Drug

Across the United States, oncologists are filing paperwork at a pace rarely seen in cancer medicine. The target: daraxonrasib, an oral pill developed by Revolution Medicines that, in a pivotal Phase 3 trial, nearly doubled median overall survival for patients with previously treated metastatic pancreatic cancer [1]. The FDA authorized an expanded access program within 48 hours of receiving the application [2], and the company says it plans to enroll approximately 900 patients [3]. For a disease that kills roughly 53,000 Americans annually and has a five-year survival rate stuck at 13%, the urgency is not hard to understand [4].

But urgency and equity do not always travel together. As academic medical centers mobilize to secure early access, community oncologists, rural hospitals, and safety-net institutions face structural barriers that could leave their patients—disproportionately lower-income and minority—on the outside of this moment.

The Data That Started the Rush

The Phase 3 RASolute 302 trial tested daraxonrasib at 300 mg once daily against investigator's choice chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results, announced in April 2026 and slated for full presentation at the ASCO Annual Meeting in late May, showed a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy—a hazard ratio of 0.40 (p < 0.0001) [5]. The trial met all primary and key secondary endpoints, including progression-free survival [5].

Source: Revolution Medicines / RASolute 302 Phase 3 Trial

Data as of May 1, 2026CSV

These numbers are striking in context. In second-line pancreatic cancer, the existing standard—typically 5-fluorouracil-based regimens or gemcitabine combinations—yields median overall survival of roughly 6 months [6]. Prior KRAS-targeted agents have produced far more modest results: sotorasib (Amgen), which targets only the rare KRAS G12C mutation found in about 1-2% of PDAC tumors, achieved an objective response rate of 21% and median overall survival of 6.9 months in a small study [7].

Daraxonrasib is mechanistically different. Rather than targeting a single KRAS variant, it is a RAS(ON) multi-selective inhibitor—meaning it blocks multiple activated forms of RAS proteins, including KRAS G12D, G12V, G12R, and others [8]. Since KRAS mutations are present in over 90% of pancreatic cancers [9], daraxonrasib has a far broader potential patient population than mutation-specific inhibitors like sotorasib or adagrasib (Mirati/Bristol Myers Squibb).

In earlier Phase 1/2 data, daraxonrasib monotherapy in treatment-naïve metastatic PDAC showed an objective response rate of 47% and a disease control rate of 89% [10]. When combined with gemcitabine and nab-paclitaxel, response rates reached 55% [10]. These numbers exceeded what most pancreatic cancer researchers expected from a single targeted agent.

Why Oncologists Say This Time Is Different

Pancreatic cancer has a long history of "promising" therapies that failed to translate into meaningful survival gains at the population level. Erlotinib, approved in 2005 in combination with gemcitabine, extended median survival by just 10 days [11]. Nanoliposomal irinotecan, approved in 2015, added about two months in the second-line setting [11]. The five-year survival rate has crept from under 5% in 2000 to 13% in recent years—incremental progress driven largely by better surgical techniques and combination chemotherapy, not targeted therapy [4].

Source: SEER/ACS Cancer Statistics

Data as of Jan 1, 2026CSV

What distinguishes daraxonrasib, according to researchers, is the combination of a validated molecular target (RAS, once considered "undruggable"), broad mutation coverage, and a Phase 3 overall survival benefit with a hazard ratio that oncologists describe as extraordinary for this disease.

Christopher Lieu, an oncology professor at the University of Colorado Anschutz Medical Campus who is not affiliated with Revolution Medicines, offered a measured assessment: "There are certain diseases where getting access to promising drugs may mean the difference between life and death, and pancreatic cancer is an example of this" [12]. But he also cautioned: "I worry sometimes about the depth of the review whenever you expedite it, because you don't want to miss important toxicity signals" [12].

The Pancreatic Cancer Action Network, the largest patient advocacy organization for the disease, described the RASolute 302 results as "a real opportunity to bring new hope for people facing this disease" [9].

The Expanded Access Scramble

The FDA received Revolution Medicines' expanded access request on April 28, 2026, and issued a "safe to proceed" letter on April 30 [2]. FDA Commissioner Marty Makary said the two-day turnaround "reflects the FDA's strong commitment to facilitate early access to therapies for serious and life-threatening conditions" [3].

The expanded access treatment protocol (EAP) is limited to patients with previously treated metastatic PDAC who have no satisfactory alternative therapies [3]. Physicians must submit requests through Revolution Medicines on behalf of eligible patients [9]. The company has stated it is "moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States" [3].

But the mechanics of expanded access programs historically favor large academic medical centers. These institutions have dedicated regulatory affairs staff, existing relationships with pharmaceutical sponsors, and the infrastructure to manage investigational drug protocols. Community oncology practices—which treat the majority of U.S. cancer patients—often lack these resources. Rural and safety-net hospitals, which serve higher proportions of Black, Hispanic, and low-income patients, face additional barriers including geographic distance from trial sites and fewer subspecialty oncologists [13].

The RASolute 302 trial itself was conducted across more than 60 sites globally [9], but public disclosures do not specify which U.S. institutions are participating in the expanded access program or how geographic distribution is being managed. Revolution Medicines has not published a list of participating sites. This opacity makes it difficult to assess whether the access scramble is reproducing the same disparities that have long characterized clinical trial enrollment in oncology.

The Ben Sasse Factor

The scramble has been amplified by high-profile advocacy. Former U.S. Senator Ben Sasse, diagnosed with stage-four pancreatic cancer in December 2025, described daraxonrasib as "a miracle drug" during a 60 Minutes interview [14]. Sasse reported a 76% reduction in tumor volume over four months on the drug [14]. His public advocacy has brought unprecedented attention to the expanded access program and to pancreatic cancer treatment broadly.

Celebrity patient stories can accelerate access—but they can also distort it. Research has consistently shown that when prominent individuals publicize their use of experimental therapies, demand surges in ways that can overwhelm supply and disproportionately benefit patients with connections, resources, and proximity to major medical centers.

The Safety Trade-Off

Daraxonrasib's efficacy data is accompanied by a real toxicity signal. Among 168 PDAC patients who received the drug at 300 mg or less in the Phase 1/2 study, 96% experienced treatment-related adverse events of any grade, and 30% experienced grade 3 or higher events [8]. The most common side effects were rash, diarrhea, stomatitis (mouth sores), and fatigue [8]. The company has characterized these as "on-target toxic effects" that were "responsive to routine clinical interventions" [8].

When combined with gemcitabine and nab-paclitaxel, grade 3 or higher toxicities rose to 73%, with rash (90% all-grade), diarrhea (75%), and fatigue (70%) as the most frequent adverse events [10].

In the pivotal RASolute 302 trial, Revolution Medicines reported that daraxonrasib was "generally well tolerated, with a manageable safety profile and with no new safety signals" [5]. Detailed adverse event data from the Phase 3 trial has not yet been publicly presented—it is expected at ASCO in late May 2026. The gap between the Phase 1/2 toxicity profile (96% any-grade adverse events) and the company's characterization of the drug as "well tolerated" warrants scrutiny once the full Phase 3 safety data is available.

The Regulatory Fast Lane

Daraxonrasib has accumulated a series of FDA designations: Breakthrough Therapy Designation (June 2025), Orphan Drug Designation, and selection for the Commissioner's National Priority Voucher pilot program (October 2025) [15][16]. Revolution Medicines has announced its intention to submit a New Drug Application under the national priority voucher pathway, which could compress the standard 10-12 month FDA review to as little as one to two months [12].

This speed raises legitimate questions. The Accelerated Approval pathway, which allows drugs to be approved based on surrogate endpoints like tumor response rate rather than overall survival, has a mixed track record. Across all oncology indications, roughly 76.5% of drugs granted accelerated approval have eventually received full approval after confirmatory trials [17]. But the track record is worse for specific cancers, and disease-free survival has uncertain validity as a surrogate for overall survival in pancreatic cancer specifically [18].

In daraxonrasib's case, however, the company appears to have a stronger foundation than most: the RASolute 302 trial demonstrated a statistically significant overall survival benefit, not merely a surrogate endpoint [5]. If the full data presented at ASCO confirms these topline results, the regulatory case for approval would rest on the hardest endpoint in oncology—actual survival—rather than on a surrogate.

Financial Anatomy of the Scramble

Revolution Medicines' stock tells a parallel story. RVMD shares have surged roughly 307% over the past year, reaching $149.94 as of May 9, 2026, with a market capitalization of $31.3 billion [19]. The company raised approximately $2.225 billion in April 2026 through concurrent stock and convertible note offerings [20], and held $1.9 billion in cash and equivalents as of March 31, 2026—before the April capital raise [20].

Source: Yahoo Finance

Data as of May 9, 2026CSV

The company reported a net loss of $453.8 million in Q1 2026, with R&D expenses of $344 million (up from $205.7 million in Q1 2025) and general/administrative expenses of $101.3 million (up from $35 million) [20]. Full-year 2026 operating expenses are projected at $1.7-1.8 billion [20]. The company has appointed regional commercial leaders in Japan, Europe, and Asia-Pacific, signaling global launch preparations [20].

Publicly available information does not detail specific advisory board fees, speaker honoraria, or equity stakes held by the oncologists most publicly associated with daraxonrasib's development. Dr. Sandra J. Horning, a former Stanford oncology professor and past ASCO president, sits on Revolution Medicines' board of directors [21]. The full RASolute 302 results will be presented at ASCO by Brian Wolpin [22]; conflict-of-interest disclosures for the presenting investigators will be published alongside the ASCO abstract but are not yet available. The CMS Open Payments database would provide additional transparency about industry payments to the physicians involved, though there is typically a two-year reporting lag.

The 90% Question

Here is the tension at the heart of the daraxonrasib story: KRAS mutations are present in over 90% of pancreatic cancers, which means the drug's potential addressable population is large [9]. But "addressable" is not the same as "served."

An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026, and about 52,740 will die of it [4]. The median time from diagnosis to death for metastatic disease is under 12 months. Revolution Medicines has not disclosed its manufacturing capacity or projected launch pricing. With the company's current cash burn rate exceeding $450 million per quarter and no revenue, the pricing question is not academic—it will determine how many of the roughly 60,000 patients per year who could theoretically benefit will actually receive the drug.

The expanded access program's cap of approximately 900 patients [3] represents a small fraction of the eligible population. For the remaining patients, access depends on either clinical trial enrollment (the Phase 3 RASolute 303 trial in the first-line setting is now enrolling [23]) or waiting for full FDA approval.

What About Everyone Else?

The intense focus on daraxonrasib raises a resource allocation question that is rarely discussed publicly. When a single drug dominates clinical attention, trial recruitment, and institutional resources, it can divert capacity from other research programs. Pancreatic cancer patients without KRAS mutations—roughly 5-10% of cases—have no prospect of benefiting from daraxonrasib [9]. And even among KRAS-mutant patients, the drug does not work for everyone: in the Phase 1/2 monotherapy data, 53% of first-line patients did not achieve an objective response [10].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The explosion of KRAS inhibitor research—nearly 50,000 papers published since 2011, peaking at over 7,300 in 2023—reflects both genuine scientific progress and the gravitational pull of a hot target. Whether this concentration of research effort comes at the expense of alternative approaches (immunotherapy combinations, stromal-targeted therapies, early detection programs) is a question that the field has not adequately reckoned with.

What Happens Next

The next inflection point is the ASCO Annual Meeting, May 29 through June 2, 2026, where the full RASolute 302 dataset will be presented in a plenary session [22]. If the detailed data—including subgroup analyses by KRAS mutation subtype, quality-of-life measures, and the complete adverse event profile—holds up to the topline announcement, Revolution Medicines will likely file its NDA shortly afterward using the national priority voucher [16].

Under that expedited pathway, FDA approval could come as early as late summer or fall 2026 [12]. The company is simultaneously running the Phase 3 RASolute 303 trial in the first-line setting [23], which, if successful, would expand the approved indication to treatment-naïve patients—a far larger population.

For the roughly 67,000 Americans who will hear the words "pancreatic cancer" this year, the arithmetic is harsh. Even with the most optimistic regulatory and manufacturing timelines, most patients diagnosed in 2026 will not have access to daraxonrasib before their disease progresses. The scramble at cancer clinics reflects a system straining to absorb a genuine therapeutic advance—while grappling with the same structural inequities that have defined American cancer care for decades.